From the lab to the bench, scaling up regulatory T cell therapy

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

From the lab to the bench, scaling up regulatory T cell therapy

Regulatory T cells (Tregs) are crucial for maintaining immune balance and preventing overactive immune responses and autoimmune diseases such as lupus and graft-versus-host disease. Restoring this balance through the expansion of Tregs offers a promising therapeutic approach. This webinar will explore a technology designed to provide an optimized activation signal for the expansion of Tregs, ensuring high-fold expansion of suppressive Tregs with a stable FOXP3 phenotype and robust suppressive function.

Join us to hear from Megan Levings, Ph.D., from the University of British Columbia and the BC Children's Hospital Research Institute, who will present compelling data on how CAR-engineered Tregs can induce immune tolerance. This breakthrough has significant implications for the treatment of autoimmune diseases, organ transplants, and stem cell transplantation. The discussion will also cover the importance of producing these therapeutics in a closed, automated environment to minimize contamination risks and human error.

Learn how a relevant number of regulatory T cells is achieved with >800-fold expansion after two stimulations
Hear how Tregs can be activated and expanded in a closed, automated system
How CAR-engineered Tregs can induce immune tolerance

Megan K. Levings

Professor, Department of Surgery and School of Biomedical Engineering at University of British Columbia

Dr Megan Levings is a Professor in the Department of Surgery and School of Biomedical Engineering at the University of British Columbia and BC Children’s Hospital Research Institute. Her laboratory studies how a special kind of white blood cell, known as a T regulatory cell, could be used as a cellular therapy to stop harmful immune responses. She is internationally recognized in the field of human immunology and leads a vibrant group of trainees and staff who are researching how to use T regulatory cells to replace conventional immunosuppression in the context of transplantation and autoimmunity. She is President Elect of the Federation of Clinical Immunology Societies and has won numerous awards, including the 2020 YWCA Woman of Distinction, Science, Research & Technology, 2022 Simon Fraser University Outstanding Alumni award, and 2022 UBC Faculty of Medicine Distinguished Researcher in the Basic/Foundational Science Category.

Hany Meås

Staff Scientist, Cell Therapy at Thermo Fisher Scientifc

Hany Meås is an R&D Staff Scientist at Thermo Fisher Scientific and the project lead for the CTS™ Detachable Dynabeads™ and the CTS™ DynaCellect™ Magnetic Separation System. Hany obtained a Bachelor’s degree in Molecular Biology from the University of Sheffield, UK, and a Master’s and PhD in Molecular Medicine from the Norwegian University of Science and Technology, Norway.

in 12

Days